Douglas Love, PRESIDENT AND CEO at Annexon, Inc. (ANNX), bought 26,065 shares at $3.83 ($100K) on 2026-09-24, disclosed to the SEC on 2026-09-25.
CEO Douglas Love purchased $99,829 of stock at $3.83, signaling confidence in the company's pipeline despite recent stock declines. This insider buying comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
The stock has dropped 23.54% over the last 30 days and is currently down 10.59% in the last 5 days, trading at $3.80, which is 47.08% below its 52-week high of $7.18.
1) Q4 2026 pivotal Phase III data readout for vonaprument in geographic atrophy (expected Q4 2026). 2) Q4 2026 assessment of the ARCHER II trial (planned Q4 2026). 3) Regulatory submissions for Guillain-Barré syndrome programs expected in 2026-2027.
The stock faces significant risk with a short interest of 18.35% of the float, and recent news indicates a second-quarter net loss of US$55.35 million, which exceeds Wall Street forecasts.
Something here stands out, but not much.
| Filing → |
| ANNX | SELL | 2023-02-17 | $39K | — | Filing → |
| ANNX | BUY | 2022-04-18 | $147K | — | Filing → |
| ANNX | SELL | 2021-09-20 | $165K | — | Filing → |